JNJ 17216498Alternative Names: JNJ-17216498
Latest Information Update: 12 Nov 2016
At a glance
- Originator Johnson & Johnson
- Class Sleep disorder therapies
- Mechanism of Action Histamine H3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Narcolepsy
Most Recent Events
- 30 Nov 2006 Phase-II clinical trials in Narcolepsy in USA (PO)